Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Long-Term Follow-Up Study of Sotatercept Added to Background Therapy in Pulmonary Arterial Hypertension
2020-005061-13Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoint: Long-term safety and tolerability of sotatercept. Started Feb 2021; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2020-005061-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005061-13.